ArticleCancer research communications2025

Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors.

Philippe A Cassier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.